Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.89M 3.35M 3.15M 2.88M 369M 5.4M 37.29M 14.41M 189M 14.62M 14.31M 599M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.56M 3.92M 3.69M 3.37M 433M 6.32M 43.68M 16.88M 221M 17.12M 16.76M 702M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 2017-06-20 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 2018-06-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 2021-03-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -0.82% | -3.57% | -3.71% | +12.92% | 48.41B | |
| -1.29% | +0.85% | +411.90% | +546.06% | 45.01B | |
| -3.20% | -0.76% | +38.11% | +18.36% | 44.07B | |
| -1.89% | -2.25% | +2.83% | +80.93% | 40.73B | |
| -1.72% | -3.07% | +13.76% | +43.40% | 33.21B | |
| -0.17% | +2.68% | - | - | 17.77B | |
| -0.07% | -0.52% | +21.34% | +117.49% | 16.5B | |
| -0.56% | -1.85% | +11.53% | +30.40% | 14.45B | |
| -2.68% | -2.60% | +71.21% | +37.36% | 13.77B | |
| Average | -0.13% | +0.20% | +70.87% | +110.87% | 30.44B | |
| Weighted average by Cap. | -1.54% | -0.12% | +86.33% | +131.34% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.38M -13.24M -12.45M -11.37M -1.46B -21.32M -147M -56.94M -746M -57.76M -56.53M -2.37B | 4.21M 3.05M 2.63M 2.47M 2.26M 290M 4.23M 29.24M 11.3M 148M 11.46M 11.22M 470M |
| Net Debt | 704K 510K 439K 413K 377K 48.42M 708K 4.89M 1.89M 24.75M 1.92M 1.88M 78.55M | 920K 667K 574K 540K 493K 63.28M 925K 6.39M 2.47M 32.35M 2.51M 2.45M 103M |
Employees
-
